Eva C Vaquero

Dr. Eva C Vaquero


Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 May 2018 in Cancer Research
Verified
Journal Article
Open access
PDF file
ISIrene Sangrador
Irene Sangrador
XMXavier Molero
Xavier Molero
FCFiona Campbell
Fiona Campbell
Sebastià Franch-ExpósitoSebastià Franch-Expósito
Sebastià Franch-Expósito
MRMaria Rovira-Rigau
Maria Rovira-Rigau
EVEva C Vaquero
Eva C Vaquero
The transcription factor Zeb1 has been identified as a crucial player in Kras-dependent oncogenesis. In pancreatic ductal adenocarcinoma (PDAC), Zeb1 is highly expressed in myofibroblasts and correlates with poor prognosis. As Kras mutations are key drivers in PDAC, we aimed here to assess the necessity of Zeb1 for Kras-driven PDAC and to define the role of Zeb1-expressing myofibroblasts in PDAC development. Genetically engineered mice with conditional pancreatic KrasG12D and Trp53 mutations (KPC) were crossed with Zeb1 haploinsufficient mice (Z+/−). Extensive PDAC was prominent in all 20-week-old KPC;Z+/+ mice, whereas only low-grade precursor lesions were detected in age-matched KPC;Z+/− littermates, with PDAC developing eventually in KPC;Z+/− aged animals. Zeb1 expression in myofibroblasts occurred early in tumorigenesis and Zeb1 haploinsufficiency retarded native expansion of stromal myofibroblasts during precursor-to-cancer progression. Zeb1 downregulation in mPSC repressed their activated gene profile, impaired their migratory and proliferative activity, and attenuated their tumor-supporting features. Conditioned media from Z+/+ mouse-activated (myofibroblast-like) pancreatic stellate cells (mPSC) boosted Ras activity in pancreatic cancer cells carrying mutant Kras; this effect was not observed when using conditioned media from Z+/− mPSC, revealing a paracrinal cooperative axis between Zeb1-expressing PSC and oncogenic Kras-bearing tumor cells. We conclude that Zeb1-expressing stromal myofibroblasts enable a heterotypic collaboration with the Kras-fated epithelial compartment, thus supporting pancreatic malignancy. Significance: Zeb1 expression in stromal myofibroblasts supports PDAC development via collaboration with the epithelial compartment bearing oncogenic Kras mutations. Cancer Res; 78(10); 2624–37. ©2018 AACR.

11 December 2021 in STAR Protocols
Verified
Journal Article
Open access
SPSilvia Pascual-Sabater
Silvia Pascual-Sabater
GRGiulia Raimondi
Giulia Raimondi
AMAna Mato-Berciano
Ana Mato-Berciano
EVEva C Vaquero
Eva C Vaquero
FAFabio Ausania
Fabio Ausania
Cristina FillatCristina Fillat
Cristina Fillat
Patient-derived organoids (PDOs) have shown the potential to reflect patient sensitivity to chemotherapeutic or targeted drugs. Recently, we showed that organoid models can also serve as a platform to screen for selectivity and potency of oncolytic adenoviruses (OAds). In this protocol, we describe the steps for tumor organoid adenoviral infection and functional assessment of patient-specific responses to OAds. We provide methods to determine OAd relative efficacy by evaluation of PDO viability after infection and adenoviral replication within cancer cells.

1 December 2014 in Cirugía Española (English Edition)
Verified
Journal Article
Closed access
DSDavid Saavedra-Perez
David Saavedra-Perez
EVEva C Vaquero
Eva C Vaquero
JAJuan-Ramon Ayuso
Juan-Ramon Ayuso
LFLaureano Fernandez-Cruz
Laureano Fernandez-Cruz

7 July 2025 in Clinical and Translational Gastroenterology
Verified
Journal Article
Open access
IAIsis K. Araujo
Isis K. Araujo
GSGuillem Soy
Guillem Soy
AGAngels Gines
Angels Gines
OSOriol Sendino
Oriol Sendino
GFGloria Fernández-Esparrach
Gloria Fernández-Esparrach
EVEva C Vaquero
Eva C Vaquero
INTRODUCTION: Accurate diagnosis of mucinous pancreatic cystic neoplasms (mPCNs) remains a clinical challenge. This study investigated the utility of single GNAS droplet-based digital polymerase chain reaction (ddPCR) analysis as a novel approach to refine the diagnostic accuracy of mPCNs using endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA). METHODS: Patients who underwent EUS-FNA and GNAS pancreatic cyst fluid (PCF) analyses for pancreatic cystic lesion (PCL) assessment were prospectively enrolled. Cysts were categorized as mPCNs, non-mPCNs, or inconclusive PCLs (iPCLs) by integrating increasing information levels: high-resolution imaging and non-DNA PCF features (level 1), GNAS PCF analysis (level 2), and surgical pathology (level 3). RESULTS: One hundred forty patients were included, 25 of whom underwent pancreatic surgery. Level 1 identified 68 mPCNs (49%), 24 non-mPCNs (17%), and 48 iPCLs (34%). GNAS mutations were detected in 42 of 68 (62%) mPCNs, 1 of 24 (4%) non-mPCNs, and 16 of 48 (33%) iPCLs. Level 2 increased mPCN detection to 62% and reduced iPCLs by one-third. Mutated GNAS showed 66% sensitivity for diagnosing mPCNs in the whole cohort and 65% in resected cases, outperforming both imaging and non-DNA PCF mucinous criteria, with 100% specificity and limited concordance with carcinoembryonic antigen, cytology, and fluid viscosity, highlighting its complementary diagnostic value. Cost-effectiveness simulations for iPCLs demonstrated that GNAS-ddPCR significantly reduced diagnostic costs by 24% compared with next-generation sequencing testing. DISCUSSION: Single GNAS-ddPCR analysis in PCF supported mPCNs diagnosis in 62% of cases and uncovered 33% of iPCLs as mPCNs with 100% specificity. It adds complementary value to standard cyst fluid markers offering a simple and cost-effective tool for improving PCL diagnosis by EUS-FNA.